Octreotide LAR in the Induction of Immunologic Response in NENs Patients
NCT04129255
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
34
Enrollment
OTHER
Sponsor class
Conditions
Neuroendocrine Tumors
Interventions
DRUG:
Octreotide Acetate
Sponsor
National Cancer Institute, Naples